JPH06172211A - アルツハイマー病の予防、治療薬 - Google Patents

アルツハイマー病の予防、治療薬

Info

Publication number
JPH06172211A
JPH06172211A JP5201519A JP20151993A JPH06172211A JP H06172211 A JPH06172211 A JP H06172211A JP 5201519 A JP5201519 A JP 5201519A JP 20151993 A JP20151993 A JP 20151993A JP H06172211 A JPH06172211 A JP H06172211A
Authority
JP
Japan
Prior art keywords
calpain
alzheimer
disease
formula
kda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5201519A
Other languages
English (en)
Japanese (ja)
Inventor
Ken-Ichi Saito
健一 斎藤
Ralph A Nixon
ラルフ・エイ・ニクソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McLean Hospital
Original Assignee
McLean Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McLean Hospital filed Critical McLean Hospital
Publication of JPH06172211A publication Critical patent/JPH06172211A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP5201519A 1992-08-14 1993-08-13 アルツハイマー病の予防、治療薬 Pending JPH06172211A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93064792A 1992-08-14 1992-08-14
US930647 1992-08-14

Publications (1)

Publication Number Publication Date
JPH06172211A true JPH06172211A (ja) 1994-06-21

Family

ID=25459574

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5201519A Pending JPH06172211A (ja) 1992-08-14 1993-08-13 アルツハイマー病の予防、治療薬

Country Status (4)

Country Link
JP (1) JPH06172211A (2)
KR (1) KR940003550A (2)
CA (1) CA2101417A1 (2)
TW (1) TW268896B (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011640A1 (en) * 1997-09-04 1999-03-11 Nippon Chemiphar Co., Ltd. Epoxysuccinamide derivatives

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116920095A (zh) * 2023-07-19 2023-10-24 江苏省原子医学研究所 一种ATP6v0c蛋白治疗阿尔茨海默病的应用方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011640A1 (en) * 1997-09-04 1999-03-11 Nippon Chemiphar Co., Ltd. Epoxysuccinamide derivatives

Also Published As

Publication number Publication date
KR940003550A (ko) 1994-03-12
CA2101417A1 (en) 1994-02-15
TW268896B (2) 1996-01-21

Similar Documents

Publication Publication Date Title
DE69625622T2 (de) Angiogenese Inhibitoren
CA2029420C (en) Pharmaceutical compositions and methods for inhibition of maillard's reaction
JP5570590B2 (ja) 虚血および虚血・再灌流障害を治療するための組成物および方法
EP0580161A1 (en) Prophylactic and therapeutic treatment of Alzheimer's disease
KR20020031331A (ko) 미토콘드리아 관련 질환의 치료방법
JP2010031059A (ja) 筋萎縮性側索硬化症を処置するためのプラミペキソールの使用
KR870001330B1 (ko) 포스포리피드 조성물의 제조방법
HU219972B (hu) 2-[N-(2-Amino-etil)-amino]-2-(2-tienil)-ecetsav és 2-[N-(2-amino-etil)-amino]-2-(2-metil-5-tienil)-ecetsav gyógyászati alkalmazásra
KR20020035855A (ko) 약용인삼을 포함하는 뇌세포 또는 신경세포 보호제
US20100068308A1 (en) Regulation of GSK-3alpha activity for the treatment or prevention of Alzheimer's disease
EP3568138B1 (en) Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
US7364719B2 (en) Vasoregulating compounds and methods of their use
KR20120008429A (ko) 마크로락틴 에이 및 그 유도체를 유효성분으로 함유하는 항혈관신생효과를 갖는 조성물
ITRM20000556A1 (it) S-adenosilmetionina e suoi derivati per il trattamento e la prevenzione della malattia di alzheimer.
CN111655254A (zh) 包含新型白杨素衍生物化合物作为活性成分的用于预防或治疗糖尿病并发症的药物组合物
CA2101417A1 (en) Prophylactic and therapeutic treatment of alzheimer's disease
JPH07316051A (ja) 免疫抑制剤としてのベルベリン
EP0998931A1 (en) Remedies for dry eye
EP0149847A2 (en) Therapeutic and preventive agent containing dolichol
WO1998010760A1 (fr) Potentialisateur d'activite de glutathione-reductase contenant de la troglitazone
JPH10101560A (ja) 神経変性疾患の予防または治療薬
JP2001513813A (ja) 副作用の少ない選択的ｍｍｐインヒビター
HUP0004647A2 (hu) Glükóz-amino-glükánok alkalmazása diabétesszel társult szembetegségek kezelésére szolgáló gyógyszerkészítmények előállítására
JPH0959158A (ja) ベンズイミダゾール誘導体を含有するぜん息治療剤
KR100356899B1 (ko) 궤양성 대장염 및/또는 크론병 예방 및 치료제